Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jul 25;13(7):1463–1480. doi: 10.21037/tlcr-24-215

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2024 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Chest CT images from a patient with tumor regrowth after initial response to TKI therapy. (A) Initial chest CT revealing a tumor in the LLL at the start of afatinib treatment (red arrow). (B) Image showing increase in size of the LLL tumor 24 months post-afatinib initiation (red arrow). (C) VATS wedge resection of the LLL tumor and mediastinal lymph node sampling. (D) CT image obtained 3 months following the wedge resection (red arrow). CT, computed tomography; TKI, tyrosine kinase inhibitor; LLL, left lower lobe; VATS, video-assisted thoracoscopic surgery.